Form 4: ResMed CFO Brett Sandercock Sells 1,000 Shares Under 10b5-1 Plan

ResMed's Chief Financial Officer, Brett Sandercock, sold 1,000 shares of common stock at a price of $212.16 per share on August 8, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On August 8, 2024, Brett Sandercock, the Chief Financial Officer of ResMed Inc., sold 1,000 shares of ResMed common stock.
• The sale was executed at a price of $212.16 per share.
• The transaction was conducted under a Rule 10b5-1 plan adopted on February 6, 2024.
• Following the transaction, Sandercock directly owns 89,056 shares of ResMed common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine transaction. The sale of shares by an executive is neither inherently positive nor negative, especially when conducted under a pre-arranged trading plan.

Industry Context

Sales by executives are a normal part of corporate governance. It is important to note that the sale was conducted under a pre-arranged 10b5-1 trading plan, which allows corporate insiders to sell shares at predetermined times and prices to avoid accusations of insider trading.

Stakeholder Impact

• The sale of shares by a high-ranking executive could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates